Ascendis Pharma is a Danish biopharmaceutical company built around its TransCon technology, which aims to deliver sustained, predictable release of parent drugs from prodrug conjugates. Its commercial focus includes rare endocrine disorders, notably once-weekly growth hormone therapy Skytrofa (lonapegsomatropin) and further candidates in areas such as hypoparathyroidism and achondroplasia. The model combines a proprietary platform with specialty endocrinology products rather than broad primary-care drugs. Physicians and patients in rare disease markets are the core audience.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 158 | — | -38.9 | — |
| Q3 2025 | 213.6 | — | -61 | — |
| Q4 2025 | 247.5 | — | -33.6 | — |
| Q1 2026 | 246.6 | — | 629.3 | — |
| Q2 2026 | 339.3 | 114.7% | 207 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Futu Holdings Limited (FUTU), Lattice Semiconductor Corporation (LSCC), H World Group Limited (HTHT), MKS Inc. (MKSI), Gen Digital Inc. (GEN), Charter Communications, Inc. (CHTR)